Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
4 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Treatment of COVID-19 patients with a SARS-CoV-2-specific siRNA-peptide dendrimer formulation.
Allergy. 2023 Jun;78(6):1639-1653. doi: 10.1111/all.15663. Epub 2023 Feb 14.
Allergy. 2023.
PMID: 36721963
Clinical Trial.
[JUSTIFICATION OF USING EQUIVALENCE OF THE INDICES OF QUALITY, SAFETY, AND EFFICACY IN DEVELOPING BIOANALOGS].
Niyazov RR, Goryachev DV, Gavrishina EV, Romodanovskii DP, Dranitsyna MA.
Niyazov RR, et al. Among authors: goryachev dv.
Eksp Klin Farmakol. 2015;78(6):37-44.
Eksp Klin Farmakol. 2015.
PMID: 26292513
Review.
Russian.
Item in Clipboard
[PLANNING THE DESIGN AND ESTIMATING THE RESULTS OF INVESTIGATIONS OF BIOEQUIVALENCE OF HIGHLY VARIABLE DRUGS BY EXAMPLE OF ROSUVASTATIN].
Romodanovskii DP, Dranitsyna MA, Goryachev DV, Niyazov RR, Gavrishina EV.
Romodanovskii DP, et al. Among authors: goryachev dv.
Eksp Klin Farmakol. 2015;78(6):19-25.
Eksp Klin Farmakol. 2015.
PMID: 26292510
Russian.
Item in Clipboard
Specific anti-IIa activity is a key indicator of safety and efficacy in validation of biosimilarity of unfractioned heparin preparations.
Mironov AN, Goryachev DV, Garvishina EV, Niyazov RR, Ivanova OY.
Mironov AN, et al. Among authors: goryachev dv.
Bull Exp Biol Med. 2015 Feb;158(4):450-2. doi: 10.1007/s10517-015-2782-3. Epub 2015 Feb 24.
Bull Exp Biol Med. 2015.
PMID: 25708323
Item in Clipboard
Cite
Cite